33 results about "Kidney inflammation" patented technology

The present invention provides one kind of acute urinary tract infection treating medicine and its preparation process. The medicine is developed based on the pathogenesis of stranguria to dredge Liver Meridian Qi stagnation and clear lower-Jiao wetness and heat. The medicine is prepared with bupleurum root, skullcap root, pinkweed and other medicine materials. Experiment shows that the medicine has the following functions: resisting Gram-negative bacterium causing urinary tract infection, reducing the inflammation reaction of kidney in urinary tract infection mouse mold, inhibiting colibacillus to adhere to bladder epidermis of mouse, inhibiting common inflammation obviously, relieving chemically caused pain of mouse abdominal cavity, increasing the post-water load urea amount of rat, etc.

The novel positively charged pro-drugs of NSAIAs in the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” were designed and synthesized. The compounds of the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” indicated above can be prepared from metal salts, organic base salts, or immobilized base salts of NSAIAs with suitable halide compounds. The positively charged amino groups in the pro-drugs in this invention largely increase the solubility of the drugs in water and will bond to the negative charge on the phosphate head group of membrane. Thus, the local concentration of the outside of the membrane or skin will be very high and will facilitate the passage of these pro-drugs from a region of high concentration to a region of low concentration. This bonding will disturb the membrane a little bit and may make some room for the lipophilic portion of the pro-drug. When the molecules of membrane move, the membrane may “crack” a little bit due to the bonding of the pro-drug. This will let the pro-drug insert into the membrane. At pH 7.4, only about 99% of the amino group is protonated. When the amino group is not protonated, the bonding between the amino group of the pro-drug and the phosphate head group of the membrane will disassociate, and the pro-drug will enter the membrane completely. When the amino group of the pro-drug flips to the other side of the membrane and thus becomes protonated, then the pro-drug is pulled into the cytosol, a semi-liquid concentrated aqueous solution or suspension. These pro-drugs can be used for treating and preventing diabetes (type I or / and type II), abnormal blood glucose and lipid levels, stroke, heart attack, and other heart and vascular diseases Alzheimer's diseases, Parkinson's diseases and other neurodegenerative diseases, psoriasis, discoid lupus erythematosus, systemic lupus erythematosus (SLE), autoimmune hepatitis, multiple sclerosis (MS), and other autoimmune diseases, amyotrophic lateral sclerosis (ALS), oculopharyngeal muscular dystrophy (OPMD), and other muscle disorders, inflamed hemorrhoids, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani, prostatitis, prostatocystitis, varicose veins, autoimmune liver inflammation, autoimmune kidney inflammation, vein inflammation and other inflammations, skin cancers, breast cancer, colon-rectum cancer, oral cancer, and other cancers, scars, abnormal vascular skin lesions, birthmarks, moles (nevi), skin tags, aging spots (liver spots), and other skin disorders. These pro-drugs can be administered transdermally without the help of skin penetration enhancers.

The invention relates to an antrodia camphorate cyclohexanedione compound used for treating autoimmune diseases and a medical composition thereof. The antrodia camphorate cyclohexanedione compound is about 4-hydroxyl-2, 3-dimethoxy-6-methyl-5(3, 7, 11-trimethyl-2, 6, 10-dodecatrien)-2-cyclohexanedione which is separated from antrodia camphorate extract and can relieve systemic erythromelalgia lupus and other symptoms caused by autoimmune diseases. Antrodia camphorate cyclohexanedione in the invention can reduce the content of urine protein of the mammalians with systemic erythromelalgia lupusand the thickness of the antinuclear antibody in blood, relieves kidney inflammation and lesion, lowers the harm of antinuclear antibody on autogenous tissues, and achieves the effect of treating autoimmune diseases such as systemic erythromelalgia lupus, and the like, and the diseases related to kidney by using natural materials without side effects.

The invention relates to Chinese medicine used for treating chronic kidney disease, especially for treating kidney inflammation, invisible kidney inflammation and nephritic syndrome, and a preparation method of the Chinese medicine. The medicine is made of yerbadetajo, Ligustrum lucidum, Leonurus japonicus, Salvia, Rehmanniae, Lonicera confuse, Madder, Lycium Chinese Mill and Scorpion. The medicine has the efficacy of replenishing vital essence, tonifying kidney-yin, activating blood and dissolving stasis. The medicine is mainly applicable to treating kidney deficiency as well as the chronic kidney disease, the invisible kidney inflammation and the nephritic syndrome and also can be used for treating the nephritic syndrome in conjunction with western medicine such as Glucocorticoid. The medicine can improve curative effect, put off recurrence and reduce the times of recurrence. The medicine of the invention can be made into any formulation which is suitable for clinical treatment, including powders, decoction, mixture, oral liquor, capsule, granular formulation and a condensed pill and so on.

The invention discloses a novel triterpene compound and application thereof to treat or prevent kidney diseases. The disclosed novel triterpene compound is capable of reducing biochemical indexes (such as content of urea nitrogen (BUN) or creatinine (CRE) in serum) related to kidney inflammation and improving glomerulus filtration rate (GFR), therefore the novel triterpene compound can be used to manufacture medicines capable of treating or preventing kidney diseases.

The invention relates to a technology for preparing compound kidney inflammation tablets, which is characterized in that crushing red sage roots 337.5g into fine powder, further mixing with baikal skullcap roots 202.5g, cattail pollen 112.5g and morning glory seeds 112.5g and crushing into fine powder, then sieving, furthermore, uniformly mixing motherwort fruits 450g, astragalus roots 337.5g, Siberian solomonseal rhizome 112.5g, poria cocos 202.5g, barbat skullcap 202.5g, doddor seeds 225g, gamene 112.5g, haw 337.5g, reed roots 202.5g, hizoma imperatae 225g, plantain seeds 225g, then adding water, and boiling the water for two hours through adding water by ten times at the first time, boiling for two hours through adding water by eight times at the second time, combining the boiled liquid, and filtering the boiled liquid, the filtering liquid is concentrated into thick paste whose relevant intensity is 1.35-1.39 (60 DEG C), adding the fine powder which is formed through mixing and crushing the scutellaria roots, the cattail pollen and the morning glory seeds, uniformly mixing, and drying the fine powder with 60 DEG C, crushing into fine powder (passing through a 100-eyes screen),lastly adding crushed red sage root fine powder and 1.0% dextrin, uniformly mixing, preparing into granules by 85% ethanol, drying with the temperature of DEG C, namely obtaining one thousand tablets. The compound kidney inflammation tablets produced by the technology have high effective component and good healing efficacy.